Teladoc Health, Inc. TDOC

A number of stocks fell in the afternoon session after the benchmark U.S. 10-year Treasury yield climbed back above 5% to levels not seen since 2007, lifting discount rates on long-duration growth earnings. According to CNBC, the 10-year yield surged to 5.23% on Friday, its highest level since 2007, after trading below 4.8% earlier in September. CNBC reported Monday that the yield was again pressing multiyear highs — above 5.23% in morning trade — as oil stayed elevated and investors braced for

Evergreen Nephrology, a leader in value-based care (VBC) programs for people with kidney disease, today announced the appointment of Brian Palo as Chief Financial Officer. As the company prepares for significant expansion over the next two years, Palo will lead strategic financial planning, capital management and investor relations while strengthening the financial infrastructure needed to scale Evergreen's model and improve outcomes for patients.

The Connected Health & Safety Association (CHS) concluded its 2026 Annual Conference in Nashville, bringing together more than 250 leaders from across healthcare, technology, senior living, caregiving, remote monitoring and aging services to explore the future of connected care and independent living.

Jonathan Dorfman to be promoted to Chief Legal Officer and Secretary effective November 2, 2026 Jonathan Dorfman Jonathan Dorfman to be promoted to Chief Legal Officer and Secretary effective November 2, 2026. NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today announced a leadership transition in its legal function. After 11 years with the company, Adam Vandervoort, Chief Legal Officer and Secretary, has informed the company o

Doximity (DOCS), which calls itself the leading digital platform for U.S. medical professionals, has seen its stock fall steeply over the past year. Even after a rise over the past three months, the shares sit about 65% below their 52-week high. Management continued its repurchase program, allocating approximately $401 million over the latest twelve months. The test is whether it can keep that up through what it calls its AI investment year.

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.

Earlier this week, Teladoc Health reported quarterly results showing a 4% year-on-year revenue decline, missing analyst expectations on both revenue and EBITDA and issuing guidance for the next quarter that also fell short of forecasts. The results highlighted a 9.2% average drop in customer spending over recent years despite user growth, alongside expectations for another period of lower revenue and negative earnings per share, underscoring pressure on Teladoc’s core business model. Now...

TD Asset Management Inc. ("TDAM") today announced the September cash distributions for the TD Exchange-Traded Funds (each, a "TD ETF" and collectively, the "TD ETFs") and TD Mutual Fund ETF Series (each, a "TD ETF Series" and collectively, the "TD ETF Series") listed below.

Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying businesses are cheap, and we advise caution as many have questionable fundamentals.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Teladoc (NYSE:TDOC) and the best and worst performers in the online marketplace industry.

Don't catch a falling knife.

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today announced that it issued inducement awards to a new employee. Effective September 1, 2026, in connection with commencing employment as Chief Financial Officer, Michael Grasher was granted an award of restricted stock units covering 239,616 shares of Teladoc Health’s common stock, par value $0.001 per share (“Common Stock”), and awards of performance stock units covering a targe

Over the past six months, Teladoc has been a great trade, beating the S&P 500 by 11.4%. Its stock price has climbed to $6.36, representing a healthy 23.2% increase. This run-up might have investors contemplating their next move.